Jasper Therapeutics (JSPR) Total Current Liabilities (2019 - 2026)

Jasper Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $7.8 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 61.73% year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $7.8 million, a 61.73% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, down 13.37% from the prior year.
• Total Current Liabilities was $7.8 million for Q2 2026 at Jasper Therapeutics, down from $13.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $21.0 million in Q3 2025, with the low at $6.0 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $11.2 million, with a median of $10.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 3202.0% in 2022, then slumped 61.73% in 2026.
• Over 5 years, Total Current Liabilities stood at $7.1 million in 2022, then surged by 75.15% to $12.4 million in 2023, then increased by 23.14% to $15.2 million in 2024, then fell by 13.37% to $13.2 million in 2025, then sank by 40.57% to $7.8 million in 2026.
• The last three Total Current Liabilities figures came in at $7.8 million (Q2 2026), $13.2 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.